XML 36 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 1,742.0 $ 1,331.2
Marketable securities 1,308.8 1,278.9
Accounts receivable, net 1,688.0 1,913.8
Due from anti-CD20 therapeutic programs 422.2 413.5
Inventory 1,254.8 1,068.6
Other current assets 767.9 881.1
Total current assets 7,183.7 6,887.1
Marketable securities 915.1 772.1
Property, plant and equipment, net 3,442.2 3,411.5
Operating lease assets 402.5 433.3
Intangible assets, net 2,385.0 3,084.3
Goodwill 5,763.9 5,762.1
Deferred tax asset 1,849.9 1,369.5
Investments and other assets 2,528.1 2,899.0
Total assets 24,470.4 24,618.9
Current liabilities:    
Taxes payable 230.9 142.0
Accounts payable 375.3 454.9
Accrued expense and other 2,741.0 3,145.3
Total current liabilities 3,347.2 3,742.2
Notes payable 7,269.2 7,426.2
Deferred tax liability 918.9 1,032.8
Long-term operating lease liabilities 363.9 402.0
Other long-term liabilities 1,356.4 1,329.6
Total liabilities 13,255.6 13,932.8
Commitments and contingencies
Biogen Idec Inc. shareholders' equity    
Preferred stock, par value $0.001 per share 0.0 0.0
Common stock, par value $0.0005 per share 0.1 0.1
Additional paid-in capital 0.0 0.0
Accumulated other comprehensive loss (171.8) (299.0)
Retained earnings 13,900.7 13,976.3
Treasury stock, at cost (2,977.1) (2,977.1)
Total Biogen Inc. shareholders’ equity 10,751.9 10,700.3
Noncontrolling interests 462.9 (14.2)
Total equity 11,214.8 10,686.1
Total liabilities and equity $ 24,470.4 $ 24,618.9